Telix Pharmaceuticals Ltd. - ADR
:TLX 9:30:00 AM EDT
| Market Cap (Intraday) | 3.77B |
| Current PE | N/A |
| Forward PE | 264.5 |
| 2yr Forward PE | 96.18 |
| 10-Day MA | $10.12 |
| 50-Day MA | $8.09 |
| 200-Day MA | $9.94 |
Telix Pharmaceuticals Ltd. - ADR Stock, :TLX
55 Flemington Road, Suite 401, Melbourne, Victoria (VIC) 3051
Australia
Phone: +61.3.9093.3855
Number of Employees:
Description
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.